Kurs & Likviditet
|2022-03-25||Ordinarie utdelning CURAS 0.00 DKK|
|2021-06-01||Extra Bolagsstämma 2021|
|2021-03-26||Ordinarie utdelning CURAS 0.00 DKK|
COPENHAGEN - Curasight A/S ("Curasight" or "the Company"). In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Curasight made by managerial employees and their closely associated persons.
The Company's managerial employees and their closely associated persons have given Curasight's power of attorney on their behalf to publish trading in Curasight's warrants of series TO 1 by the Company's managerial employees and their closely associated persons. Curasight's managerial employees and their closely associated persons have exercised all their warrants of series TO 1.
The warrants of series TO 1 were issued in connection with the Company's IPO in September 2020. The transactions comprise all (100%) available warrants of series TO 1 of the following managerial employees and their closely associated persons;
Name Position Aggregated volume Price, DKK
Per Falholt Chairman of the 30,380 522,536.00
Board of directors
Lars Trolle Deputy chairman of 9,114 156,760.80
the Board of
Charlotte Member of the Board 24,304 418,028,80
Vedel of directors
Andreas Kjær CSO and member of 6,076 104,507.20
the Board of
Ulrich CEO and member of 6,076 104,507.20
Krasilnikoff the Board of
Total 75,950 1,306,340.00
Curasight issued units (shares and consideration free warrants) in connection with the Company's IPO in September 2020, as well as the Private Placement that was executed in parallel with the IPO. Each unit consisted of eight shares and seven warrants. During the exercise period for the warrants of series TO 1, each warrant holder has the possibility, for each warrant, to subscribe for one new share in Curasight for DKK 17.20 per share. The exercise period ends on 7 October 2021.
The proceeds that the Company will receive through the warrant exercise will finance Curasight's clinical development plan.